GlassScriptPhysician profile
Mai T Pham
NPI 1912171703
$16,844.43
in general payments reported to CMS, 2019-2025
27 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,591 · 2020: $179 · 2021: $732 · 2022: $1,099 · 2023: $810 · 2024: $1,343 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,950 · Food and Beverage: $4,434 · Consulting Fee: $1,650 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Travel and Lodging: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,950.00 |
| Food and Beverage | $4,433.94 |
| Consulting Fee | $1,650.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Travel and Lodging | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $8,632.25 | 2019-2025 | Cequa, Bromsite |
| Johnson & Johnson Surgical Vision, INC. | $2,782.20 | 2019-2025 | Lipiflow System Activator (Disposable), Tecnis Simplicity, Lipiview Ocular Surface Interferometer |
| Glaukos Corporation | $1,250.56 | 2019-2021 | |
| Abbvie INC. | $789.21 | 2022-2025 | |
| Alcon Vision LLC | $781.05 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Allergan, INC. | $555.64 | 2019-2021 | |
| Harrow Eye, LLC | $266.93 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $234.53 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $232.16 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $210.46 | 2021-2022 | |
| Dompe US, INC. | $194.72 | 2025 | Oxervate |
| Boston Scientific Corporation | $106.81 | 2025 | Avvigo Guidance System |
| Aerie Pharmaceuticals, INC. | $103.91 | 2019-2021 | |
| Tela Bio, INC. | $103.00 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Thea Pharma INC. | $101.69 | 2022-2025 | Iyuzeh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $99.46 | 2019-2022 | |
| Amgen INC. | $91.98 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $77.13 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $58.29 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.07 | 2019 | |
| Sight Sciences, INC. | $35.20 | 2019-2022 | |
| Rxsight INC | $21.22 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ani Pharmaceuticals, INC. | $19.23 | 2024 | Purified Cortrophin Gel |
| Shire North American Group INC | $18.38 | 2019 | |
| Biotissue Holdings INC. | $15.95 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mai Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.